|Chennai||Rs. 27770.00 (-0.14%)|
|Mumbai||Rs. 29200.00 (2.31%)|
|Delhi||Rs. 27900.00 (-0.36%)|
|Kolkata||Rs. 28270.00 (1%)|
|Kerala||Rs. 27050.00 (-0.37%)|
|Bangalore||Rs. 27550.00 (1.66%)|
|Hyderabad||Rs. 27770.00 (-0.14%)|
Shares in Indian drugmakers fall on speculation the government's final decision on the pricing policy for the sector might be more disruptive than expected.
Local media reports suggest a panel of ministers has agreed to settle on a market-based pricing mechanism, as expected, but capping drug prices at a simple average price of brands as opposed to the initial proposal of using a weighted average.
The proposal, if finalised, would be "incrementally negative" for the sector, but the impact would vary from company to company, Nomura says in a note on Thursday.
Dr Reddy's Laboratories is flat, Glenmark Pharmaceuticals is up 3.9 percent and Cadila gains 2.2 percent.